Microsoft: A Critical Point in Valuation Momentum
May 22, 2025 How Measurement and Mix Modeling Drive Better Business Decisions
May 22, 2025 Are you making these mistakes when analyzing candlestick patterns?
April 23, 2025 Oleksandr Orlovskyi: Reviews, Biography, and All About Cryptocurrency
March 12, 2025 Features of exchanging USDC ERC20 to Bank Transfer
February 19, 2025 Why Stock Caps Matter When Building a Diversified Portfolio
Thermo Fisher Scientific (TMO) Stock Forecast for 2025, 2026, 2027. Sell or Buy?
Updated: May 24, 2025 (21:31)
Sector: HealthcareThe share price of Thermo Fisher Scientific Inc. (TMO) now
Analysts predictions
Full report
This Week
|
Neutral | Opinions: 1 |
Previous Week
|
Neutral | Opinions: Na |
Two Weeks Ago
|
Neutral | Opinions: 1 |
Three Weeks Ago
|
Bullish | Opinions: 1 (1/0/0) |
Are you interested in Thermo Fisher Scientific Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Thermo Fisher Scientific stock price in 2025, 2026, 2027. How much will one Thermo Fisher Scientific share be worth in 2025 - 2027?
When should I take profit in Thermo Fisher Scientific stock? When should I record a loss on Thermo Fisher Scientific stock? What are analysts' forecasts for Thermo Fisher Scientific stock? What is the future of Thermo Fisher Scientific stock? We forecast Thermo Fisher Scientific stock performance using neural networks based on historical data on Thermo Fisher Scientific stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
Thermo Fisher Scientific stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2025, 2026, 2027, and ) The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Thermo Fisher Scientific shares. This happens once a day.
Historical and forecast chart of Thermo Fisher Scientific stock
The chart below shows the historical price of Thermo Fisher Scientific stock and a prediction chart for the next month.
For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast,
and Weighted Average Best Forecast. Detailed values for the Thermo Fisher Scientific stock price can be found in the table below.
Long-term forecasts by years.
Thermo Fisher Scientific Inc. Analysts predictions review

Thermo Fisher Scientific faces short-term challenges from tariffs and macroeconomic pressures, which could compress margins in certain segments. Despite these headwinds, the company's operational resilience, strong pricing power, and diversified portfolio position it well to navigate geopolitical uncertainties. Growth in life sciences tools and diagnostics and a proven track record of innovation and strategic acquisitions ensure durable competitive advantages. While current valuation reflects these strengths and may limit immediate upside, Thermo Fisher remains poised for long-term growth driven by structural demand in healthcare and diagnostics.

Thermo Fisher: Navigating Tariff Challenges with Strong Valuation Support

Thermo Fisher Scientific's exposure to tariffs has introduced a cost headwind that could weigh on near-term margins. The broader economic environment also raises concerns about squeezed profitability in certain product segments, especially those with higher supply chain dependence. However, the company's strong pricing power and strategic cost management partially mitigate the impact of these external pressures, providing investors some reassurance.
Valuation as a Balancing Factor
The valuation of TMO remains a compelling case for investors, as the stock's current multiples appear attractive relative to historical levels. The author's assessment suggests that the underappreciation of Thermo Fisher's long-term growth potential may compensate for the tariff-induced downside risks, which should help stabilize investor sentiment.
Additionally, the company's robust track record of innovation and acquisitions positions it for sustained growth, even amid macroeconomic uncertainties. These structural advantages are likely to preserve TMO's competitive moat and drive shareholder value over the medium to long term.

Thermo Fisher Scientific: Evaluating Policy Impacts and Industry Resilience

Thermo Fisher Scientific's performance is significantly influenced by ongoing tariff and policy developments, which appear to be largely accounted for in its current valuation. The market’s pricing reflects cautious optimism about the company’s ability to mitigate potential regulatory headwinds, a view supported by the author's analysis.
Operational Adaptability and Growth Prospects
The company's operational resilience, particularly in navigating geopolitical and trade uncertainties, positions it as a stable player in a volatile macroeconomic environment. The author underscores how Thermo Fisher’s diversified product portfolio and strategic partnerships serve as buffers against policy-driven challenges.
Additionally, growth in sectors such as life sciences tools and diagnostics underscores a robust demand profile, which could catalyze long-term growth. The summary suggests that the company’s proactive strategies, including innovation and market expansion, are key levers to counteract external pressures and sustain earnings momentum.
However, pricing in already accounts for these resilience factors, leaving limited immediate upside for the stock. The analytical stance hints at a neutral near-term outlook with a focus on monitoring further policy shifts and macroeconomic trends.

Evaluating Thermo Fisher Scientific's Growth Potential Amid Industry Dynamics

The company's robust revenue growth has been a key driver of stability and investor confidence. Array highlights Thermo Fisher Scientific's ability to leverage its scale and operational efficiency to deliver consistent top-line growth, particularly in sectors like healthcare and life sciences.
Operational Excellence and Competitive Strength
Thermo Fisher's strategic acquisitions have positioned it as a leader in the scientific instruments and laboratory supplies industry. Array notes that these acquisitions not only expand the company's product portfolio but also strengthen its competitive moat, ensuring sustained industry leadership.
R&D investment has been critical in fostering innovation and ensuring long-term relevance. According to Array, the company's focus on emerging technologies gives it an edge in adapting to evolving market needs, which could further drive stock performance.
Macroeconomic factors, such as increased global demand for healthcare and diagnostics, provide a tailwind for growth. Array emphasizes how Thermo Fisher is well-positioned to capitalize on these trends to achieve sustained profitability.
Valuation concerns are noted, with Array suggesting that the company's premium valuation may limit upside potential in the near term. However, this pricing reflects its strong fundamentals and growth outlook.
Thermo Fisher Scientific (TMO) reported a strong performance in the fourth quarter, driven by robust demand across its core business segments. The company’s ability to adapt to macroeconomic challenges while maintaining operational efficiency demonstrates resilience and underscores its position as a leader in the life sciences sector.
Strategic Positioning and Growth Drivers
The company’s strategic mergers and acquisitions (M&A) initiatives continue to be important growth drivers, with recent deals complementing its existing portfolio and enhancing its value proposition in critical markets. As highlighted by the author, the effective integration of these acquisitions has meaningfully expanded TMO’s reach and innovation capabilities, contributing positively to its stock valuation.
TMO's investments in emerging areas of life sciences, including biotechnology and personalized medicine, are laying the foundation for sustained long-term growth. These initiatives are not only capitalizing on high-growth segments but are also differentiating the company from competitors, a factor likely to support its valuation premium in the near term.
Market dynamics, including steady demand for research tools and diagnostics, provide TMO with a resilient revenue base. Despite potential headwinds such as currency fluctuations and inflation, the company’s diversified portfolio and pricing power mitigate risks, making the stock an attractive option for growth-oriented investors.
Thermo Fisher Scientific's growth outlook appears strong, underpinned by its robust focus on expanding life sciences and diagnostics capabilities. The company's reinvestment into its core R&D, coupled with strategic acquisitions, positions it as a leader in high-growth markets, which could significantly lift revenue momentum in the coming quarters.
Strong Operational Execution and Market Leadership
The company's consistent ability to execute operational improvements continues to bolster its competitive edge. According to the author, this operational efficiency not only enhances profitability but also supports sustained innovation investments, which are key to maintaining its market leadership.
Additionally, Thermo Fisher's strategic diversification across healthcare, industrial, and academic markets provides solid insulation against sector-specific headwinds. This balanced exposure broadens its revenue streams, reducing risks and supporting steady free cash flow generation, a critical driver of shareholder value.
Despite near-term economic uncertainties, strong secular trends in biotechnology and healthcare R&D remain key tailwinds for the company. As the author suggests, these dynamics could fuel Thermo Fisher's organic growth, especially as demand for advanced diagnostic and lab solutions continues to rise globally.
Thermo Fisher Scientific (TMO) is grappling with a notable slowdown in organic revenue growth, a factor likely driven by weaker demand in legacy markets and macroeconomic pressures. This deceleration may strain its valuation metrics in the short term, as investors typically reward consistent growth for companies in the life sciences and diagnostics sectors.
A rising cost structure is another emerging challenge, particularly as inflationary trends and supply chain disruptions elevate operational expenses. The company's ability to safeguard margins will become a critical determinant of its stock performance, as missteps here could erode investor confidence further.
Potential Margin Pressures and Long-Term Implications
The article highlights that Thermo Fisher's capital allocation strategy and M&A activity have slowed in the current environment. This could limit its capacity to drive the inorganic growth that has historically supported its share price, adding another layer of uncertainty for investors.
Lastly, the global macroeconomic environment poses overarching headwinds, including foreign exchange volatility and tightening monetary policies. These external factors threaten to suppress earnings growth and may keep the stock range-bound or slightly pressured in the near term.
Thermo Fisher Scientific (TMO) continues to position itself as a leader in the high-growth biologicals market, a sector with significant long-term potential. The company's strategic focus on expanding its offerings in this space aligns with the rising demand for biologics in healthcare, underscoring its capacity to capture a growing share of this multi-billion-dollar industry. The author emphasizes that this pivot towards biologicals is a critical growth accelerator, likely translating into robust revenue gains.
Key Factors Driving TMO's Investment Appeal
The integration of recent acquisitions into Thermo Fisher’s operational framework has strengthened its product pipeline and widened its competitive moat. These acquisitions not only enhance the company’s capability to meet current market demand but also create additional synergies, potentially driving margin expansion in the near to medium term.
Investment in advanced manufacturing and R&D facilities further cements Thermo Fisher’s ability to innovate and scale its biologicals portfolio. This proactive strategy positions the company to stay ahead of evolving market trends and capitalize on the increasing use of biologics in precision medicine and therapeutics.
The company’s robust financial position, marked by consistent cash flow generation and prudent capital allocation, ensures ample capacity to fund growth initiatives. As highlighted by the author, this financial strength mitigates risk and supports long-term value creation, making TMO an attractive stock for growth-oriented investors.
Given the favorable trends within the broader healthcare sector and Thermo Fisher’s leadership in emerging growth areas like biologicals, investor confidence is likely to remain strong. The diversification of the revenue base and exposure to high-margin businesses signal sustained momentum for the company’s stock price in the coming quarters.
Thermo Fisher Scientific has exhibited early signs of cyclical recovery, supported by key operational and strategic initiatives that could bolster investor confidence in the near term. The company's focus on capturing market share through innovation and strategic acquisitions appears aligned with a broader industry rebound, positioning it favorably against macroeconomic headwinds.
Strategic Strengths and Market Implications
TMO's recent emphasis on strengthening its core business segments, particularly life sciences and analytical instruments, is a notable growth driver. These segments stand well-positioned to capitalize on a post-pandemic uptick in research and development activities, potentially accelerating revenue growth.
The stabilization of supply chains and easing inflationary pressures are additional positives for TMO’s margin expansion capabilities. By optimizing cost structures and addressing previous operational constraints, the company is better prepared to navigate competitive pressures and deliver consistent earnings performance.
Furthermore, the article highlights Thermo Fisher's commitment to long-term shareholder value through disciplined capital allocation and dividend reliability. These efforts may enhance the stock's appeal to income-focused investors, particularly as confidence in the broader market recovery solidifies.
Thermo Fisher Scientific (TMO) demonstrates solid growth prospects driven by its diversified portfolio and operational resilience. The company's ability to consistently generate revenue from both healthcare-related and industrial applications positions it to remain a key player in multiple high-growth markets, with a notable emphasis on its diagnostic and life sciences instruments.
Strategic Initiatives and Market Expansion
Operational efficiencies and strategic acquisitions continue to be critical drivers for TMO. The company's past acquisitions, such as PPD and QIAGEN, highlight its strong initiative for vertical integration and expanding its presence in clinical research and diagnostics, which could fuel revenue growth in the coming quarters.
Another essential factor is the expected resurgence in demand for lab equipment and life sciences tools post-pandemic. As research funding normalizes and industrial activities gain momentum, TMO stands to capitalize on increasing demand in its end markets.
Finally, its robust capital allocation strategy ensures healthy reinvestments into R&D while maintaining a consistent dividend payout. This approach highlights financial discipline and reinforces its long-term growth trajectory, providing investors with both growth and income opportunities.
Thermo Fisher Scientific's focus on mergers and acquisitions (M&A) demonstrates a strategic approach to strengthening its market position and expanding its product portfolio. The author's analysis highlights that these acquisitions not only enhance the company's revenue streams but also provide synergies that improve operational efficiency—a critical factor for long-term growth.
Innovation through consistent investment in research and development (R&D) is a cornerstone of Thermo Fisher's strategy. As the author points out, this commitment to R&D underpins sustained innovation in life sciences and healthcare technology, directly boosting its competitive edge and supporting sales growth in high-demand sectors.
Market Dynamics and Shareholder Returns
The company's diversified revenue base across various industries, including healthcare, diagnostics, and pharmaceuticals, acts as a buffer against macroeconomic volatility. The author emphasizes that this diversification reduces risk, enhances revenue predictability, and strengthens Thermo Fisher's ability to weather economic downturns.
Finally, ongoing efficiency initiatives and cost management bolster the bottom line and improve margin profiles, which are critical for maintaining shareholder returns. The author's position that these factors should support near-term and medium-term stock price appreciation appears well-founded.
Thermo Fisher Scientific (TMO) is positioned near attractive valuation levels, boosted by its robust fundamentals and potential to deliver long-term growth. The company's defensive business model and diversified portfolio offer a margin of safety, which can cushion against near-term macroeconomic pressures. The author underscores how this stability makes TMO appealing for value-oriented and long-term investors.
Key Catalysts Driving TMO's Stock Potential
The company benefits significantly from its strong presence in the life sciences and diagnostics market, which continues to demonstrate resilient demand despite cyclical challenges. According to the author, this non-discretionary revenue base sets TMO apart as a defensive growth opportunity in an uncertain broader market environment.
Operational efficiency and strategic capital allocation have been instrumental in preserving TMO's profitability. Investments in high-margin verticals and aggressive share buybacks signal management's confidence, potentially supporting earnings per share (EPS) growth and share price appreciation.
Concerns regarding near-term headwinds, such as an uncertain macroeconomic backdrop or potential supply chain constraints, might cap immediate upside. However, the stock's compelling valuation metrics, including a price-to-earnings ratio below its historical average, provide downside protection and room for multiple expansion as conditions improve.
Fisher Scientific is an American biotechnology company.
Thermo Fisher Scientific daily forecast for a month
Date | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
May 26 | 396.07 | 393.69 | 399.32 | 1.43 |
May 27 | 395.04 | 392.04 | 397.65 | 1.43 |
May 28 | 397.57 | 392.56 | 401.70 | 2.33 |
May 29 | 400.19 | 396.75 | 402.03 | 1.33 |
May 30 | 406.76 | 405.13 | 408.54 | 0.84 |
May 31 | 404.88 | 401.56 | 410.23 | 2.16 |
Jun 01 | 405.05 | 399.70 | 410.55 | 2.72 |
Jun 02 | 405.77 | 400.26 | 410.81 | 2.64 |
Jun 03 | 400.66 | 397.14 | 403.63 | 1.63 |
Jun 04 | 398.02 | 392.37 | 400.57 | 2.09 |
Jun 05 | 398.97 | 394.11 | 405.12 | 2.79 |
Jun 06 | 398.57 | 395.62 | 402.00 | 1.61 |
Jun 07 | 404.39 | 402.69 | 409.41 | 1.67 |
Jun 08 | 404.15 | 399.79 | 406.25 | 1.62 |
Jun 09 | 411.34 | 405.75 | 414.39 | 2.13 |
Jun 10 | 418.34 | 412.23 | 421.43 | 2.23 |
Jun 11 | 416.50 | 413.66 | 418.16 | 1.09 |
Jun 12 | 420.41 | 414.36 | 423.52 | 2.21 |
Jun 13 | 418.73 | 416.72 | 420.41 | 0.88 |
Jun 14 | 414.38 | 409.98 | 418.44 | 2.06 |
Jun 15 | 412.80 | 408.59 | 415.86 | 1.78 |
Jun 16 | 405.70 | 403.59 | 411.06 | 1.85 |
Jun 17 | 408.54 | 406.01 | 411.56 | 1.37 |
Jun 18 | 414.26 | 409.79 | 417.41 | 1.86 |
Jun 19 | 418.73 | 416.47 | 425.27 | 2.11 |
Jun 20 | 426.35 | 424.05 | 429.68 | 1.33 |
Jun 21 | 420.64 | 418.88 | 424.76 | 1.41 |
Jun 22 | 424.01 | 419.09 | 428.42 | 2.23 |
Jun 23 | 423.67 | 421.04 | 428.92 | 1.87 |
Jun 24 | 422.06 | 419.44 | 426.11 | 1.59 |
Thermo Fisher Scientific Daily Price Targets
Thermo Fisher Scientific Stock Forecast 05-26-2025.
Forecast target price for 05-26-2025: $396.07.
Positive dynamics for Thermo Fisher Scientific shares will prevail with possible volatility of 1.408%.
Pessimistic target level: 393.69
Optimistic target level: 399.32
Thermo Fisher Scientific Stock Forecast 05-27-2025.
Forecast target price for 05-27-2025: $395.04.
Negative dynamics for Thermo Fisher Scientific shares will prevail with possible volatility of 1.411%.
Pessimistic target level: 392.04
Optimistic target level: 397.65
Thermo Fisher Scientific Stock Forecast 05-28-2025.
Forecast target price for 05-28-2025: $397.57.
Positive dynamics for Thermo Fisher Scientific shares will prevail with possible volatility of 2.276%.
Pessimistic target level: 392.56
Optimistic target level: 401.70
Thermo Fisher Scientific Stock Forecast 05-29-2025.
Forecast target price for 05-29-2025: $400.19.
Positive dynamics for Thermo Fisher Scientific shares will prevail with possible volatility of 1.314%.
Pessimistic target level: 396.75
Optimistic target level: 402.03
Thermo Fisher Scientific Stock Forecast 05-30-2025.
Forecast target price for 05-30-2025: $406.76.
Positive dynamics for Thermo Fisher Scientific shares will prevail with possible volatility of 0.836%.
Pessimistic target level: 405.13
Optimistic target level: 408.54
Thermo Fisher Scientific Stock Forecast 05-31-2025.
Forecast target price for 05-31-2025: $404.88.
Negative dynamics for Thermo Fisher Scientific shares will prevail with possible volatility of 2.112%.
Pessimistic target level: 401.56
Optimistic target level: 410.23
TMO (TMO) Monthly Stock Prediction for 2025
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jun. | 401.07 | 389.44 | 430.35 | 9.51 |
Jul. | 382.62 | 353.54 | 401.75 | 12.00 |
Aug. | 385.68 | 358.30 | 399.18 | 10.24 |
Sep. | 359.45 | 342.92 | 384.26 | 10.76 |
Oct. | 368.80 | 341.14 | 389.45 | 12.41 |
Nov. | 378.39 | 363.25 | 407.90 | 10.95 |
Dec. | 367.42 | 360.07 | 380.27 | 5.31 |
Thermo Fisher Scientific forecast for this year
Thermo Fisher Scientific Stock Prediction for Jun 2025
An uptrend is forecast for this month with an optimal target price of $401.068. Pessimistic: $389.44. Optimistic: $430.35
Thermo Fisher Scientific Stock Prediction for Jul 2025
An downtrend is forecast for this month with an optimal target price of $382.619. Pessimistic: $353.54. Optimistic: $401.75
Thermo Fisher Scientific Stock Prediction for Aug 2025
An uptrend is forecast for this month with an optimal target price of $385.68. Pessimistic: $358.30. Optimistic: $399.18
Thermo Fisher Scientific Stock Prediction for Sep 2025
An downtrend is forecast for this month with an optimal target price of $359.454. Pessimistic: $342.92. Optimistic: $384.26
Thermo Fisher Scientific Stock Prediction for Oct 2025
An uptrend is forecast for this month with an optimal target price of $368.799. Pessimistic: $341.14. Optimistic: $389.45
Thermo Fisher Scientific Stock Prediction for Nov 2025
An uptrend is forecast for this month with an optimal target price of $378.388. Pessimistic: $363.25. Optimistic: $407.90
Thermo Fisher Scientific Stock Prediction for Dec 2025
An downtrend is forecast for this month with an optimal target price of $367.415. Pessimistic: $360.07. Optimistic: $380.27
Thermo Fisher Scientific (TMO) Monthly Stock Prediction for 2026
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 384.68 | 367.37 | 399.30 | 8.00 |
Feb | 367.37 | 339.09 | 387.58 | 12.51 |
Mar | 397.87 | 379.96 | 429.69 | 11.57 |
Apr | 377.18 | 352.66 | 391.51 | 9.92 |
May | 384.34 | 367.05 | 404.33 | 9.22 |
Jun | 420.09 | 396.14 | 447.39 | 11.46 |
Jul | 402.86 | 383.12 | 412.53 | 7.13 |
Aug | 424.21 | 406.82 | 456.45 | 10.87 |
Sep | 428.46 | 407.46 | 443.88 | 8.20 |
Oct | 431.46 | 399.53 | 444.40 | 10.10 |
Nov | 421.10 | 408.89 | 434.58 | 5.91 |
Dec | 417.73 | 387.24 | 435.28 | 11.04 |
Thermo Fisher Scientific (TMO) Monthly Stock Prediction for 2027
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 412.30 | 403.23 | 435.39 | 7.39 |
Feb | 392.92 | 374.46 | 405.50 | 7.66 |
Mar | 409.82 | 395.89 | 419.24 | 5.57 |
Apr | 388.92 | 363.25 | 415.75 | 12.63 |
May | 427.03 | 397.57 | 446.25 | 10.91 |
Jun | 417.64 | 394.25 | 436.85 | 9.75 |
Jul | 435.60 | 410.33 | 458.25 | 10.46 |
Aug | 454.33 | 434.79 | 481.59 | 9.72 |
Sep | 446.15 | 413.13 | 458.19 | 9.83 |
Oct | 468.46 | 432.38 | 498.44 | 13.25 |
Nov | 462.37 | 442.95 | 478.55 | 7.44 |
Dec | 427.69 | 416.57 | 456.77 | 8.80 |
Thermo Fisher Scientific information and performance
168 THIRD AVENUE, WALTHAM, MA, US
Market capitalization of the Thermo Fisher Scientific Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of TMO shares in the company outstanding by the market price of one share.
EBITDA of Thermo Fisher Scientific is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
Thermo Fisher Scientific (TMO) stock dividend
Thermo Fisher Scientific last paid dividends on 03/14/2025. The next scheduled payment will be on 04/15/2025. The amount of dividends is $1.6 per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.
Last Split Date: 01/01/1970
Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.
For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.
FAQ (Frequently Asked Questions about Thermo Fisher Scientific Stock)
Should I Buy Thermo Fisher Scientific Shares in 2025 year?
Does Thermo Fisher Scientific pay dividends?
Which economic sector do Thermo Fisher Scientific's shares belong to?
Which other securities belong to the same sector as Thermo Fisher Scientific's shares?
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.